MNOV
MediciNova, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.63
+0.62%Aug 19, 2026, 00:00 UTC
MediciNova Inc. announced the appointment of Yuichi Iwaki as President and Chief Executive Officer and Kazuko Matsuda as Chief Medical Officer, effective August 17, 2026, with compensation packages including base salaries and severance terms.
Aug 13, 2026, 23:51 UTC
MediciNova reported a Q2 2026 net loss of $0.05 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from a $0.07 loss a year earlier.
Source:Jul 15, 2026, 12:00 UTC
MediciNova announced that the SEANOBI-ALS study evaluating MN-166 (ibudilast) in ALS patients achieved its target enrollment of 200 patients.
Source:Jun 8, 2026, 12:00 UTC
MediciNova received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering use of MN-166 with anti-PD-1 inhibitor for glioblastoma treatment.
Source: